SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer…

Artiva Biotherapeutics, Inc. · 8-K filed Feb 24, 2026 at 17:14 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Feb 24, 2026 at 17:14 ET

Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer effective February 18, 2026. Huston receives an annual base salary of $540,000 and an inducement grant of 220,000 restricted stock units, with vesting over four years. The appointment reflects a strategic leadership addition in the biotech firm's financial management.

  • Thad Huston appointed CFO effective February 18, 2026
  • Annual base salary of $540,000 with 40% target bonus
  • Inducement grant of 220,000 RSUs under 2025 Inducement Plan
  • RSUs vest over four years: 25% on February 15, 2027, then quarterly

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access